Skip to Content

Pathfinder Cell Therapy Inc PFND

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

PFND is trading at a 186% premium.
Price
$0.00
Fair Value
$5.64
Uncertainty
Extreme
1-Star Price
$2.38
5-Star Price
$4.79
Economic Moat
Nzvnrl
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PFND is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.00
Market Cap
$667.16
Volume/Avg
500 / 3,450

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Pathfinder Cell Therapy Inc is a regenerative medicine company. It is engaged in developing novel cell-based and related therapies for the treatment of diabetes, renal diseases and medical conditions characterized by organ-specific cell damage. Further, the group has discovered a new mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (“PCs”) themselves being incorporated into the new tissue. Geographically the business activities are functioned through the region of United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
1

Valuation

Metric
PFND
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
PFND

Financial Strength

Metric
PFND
Quick Ratio
0.00
Current Ratio
0.00
Interest Coverage
−2.54
Quick Ratio
PFND

Profitability

Metric
PFND
Return on Assets (Normalized)
−1,542.86%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
PFND
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
FlzrqxnjkHsrxx$598.1 Bil
Vertex Pharmaceuticals Inc
VRTX
GmyznzwXzqvbr$126.0 Bil
Regeneron Pharmaceuticals Inc
REGN
QcgyxmcctJbkctrl$119.6 Bil
Moderna Inc
MRNA
CgblmjgThvtj$47.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
VksthhzFlccvr$30.4 Bil
argenx SE ADR
ARGX
YzngfrxwTbj$27.4 Bil
BioNTech SE ADR
BNTX
DwlgbjnxPfwnc$20.8 Bil
Biomarin Pharmaceutical Inc
BMRN
JgccktwvNjpmjq$16.1 Bil
United Therapeutics Corp
UTHR
QnxystfpRsvx$14.7 Bil
Incyte Corp
INCY
NnswjgdsLmndf$12.9 Bil

Sponsor Center